Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Sanofi is paying up to US $1.6 billion for Vicebio, taking UQ’s Molecular Clamp vaccine tech global in Australia’s biggest university IP exit.

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Sanofi’s $1.76 billion acquisition of Vicebio delivers a windfall for the University of Queensland — and highlighted a ...

It’s not a love-in yet and Hutchies boss Scott Hutchinson still reckons unions are “a pain in the ass” but relations are improving with just seven years to go before the opening ceremony of the 2032 ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

A UK company developing technology spun out of the University of Queensland is poised for growth after being acquired by ...

The US Securities and Exchange Commission has subpoenaed information from Telix, in relation to the company's therapeutic ...

Sanofi acquires UQ-linked biotech Vicebio for up to US$1.6b, marking Australia’s largest university commercialisation deal.